300110.SZ
Huaren Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 2.80
−2.10%Year over year
Reported trailing growth
- Revenue
- +6.2%
- EBITDA
- —
- EBIT
- +67.7%
- EPS
- +67.0%
- Free cash flow
- +3.6%
- Operating cash flow
- -0.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -6.6%
- EBITDA
- +72.3%
- EBIT
- +66.3%
- Net income
- +66.2%
- EPS
- +66.2%
- Free cash flow
- +24.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026